Alembic Pharma Successfully Passes USFDA Inspection at Panelav Oncology Facility

BILKULONLINE

Mumbai, Oct 9: Alembic Pharmaceuticals today announced that it has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav.

The inspection was successfully completed without any Form 483 observation. The inspection was conducted from 7^th October, 2024 to 8^th October, 2024.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.